Literature DB >> 32471935

Successful Pseudomonas aeruginosa eradication improves outcomes after lung transplantation: a retrospective cohort analysis.

Benedicte De Muynck1,2, Anke Van Herck3,2, Annelore Sacreas3, Tobias Heigl3, Janne Kaes3, Arno Vanstapel3, Stijn E Verleden3, Arne P Neyrinck4, Laurens J Ceulemans5, Dirk E Van Raemdonck3,5, Katrien Lagrou6,7, Bart M Vanaudenaerde3, Geert M Verleden1,3, Robin Vos8,3.   

Abstract

Long-term survival after lung transplantation (LTx) is hampered by development of chronic lung allograft dysfunction (CLAD). Pseudomonas aeruginosa is an established risk factor for CLAD. Therefore, we investigated the effect of P. aeruginosa eradication on CLAD-free and graft survival.Patients who underwent first LTx between July, 1991, and February, 2016, and were free from CLAD, were retrospectively classified according to P. aeruginosa presence in respiratory samples between September, 2011, and September, 2016. P. aeruginosa-positive patients were subsequently stratified according to success of P. aeruginosa eradication following targeted antibiotic treatment. CLAD-free and graft survival were compared between P. aeruginosa-positive and P. aeruginosa-negative patients; and between patients with or without successful P. aeruginosa eradication. In addition, pulmonary function was assessed during the first year following P. aeruginosa isolation in both groups.CLAD-free survival of P. aeruginosa-negative patients (n=443) was longer compared with P. aeruginosa-positive patients (n=95) (p=0.045). Graft survival of P. aeruginosa-negative patients (n=443, 82%) was better compared with P. aeruginosa-positive patients (n=95, 18%) (p<0.0001). Similarly, P. aeruginosa-eradicated patients demonstrated longer CLAD-free and graft survival compared with patients with persistent P. aeruginosa Pulmonary function was higher in successfully P. aeruginosa-eradicated patients compared with unsuccessfully eradicated patients (p=0.035).P. aeruginosa eradication after LTx improves CLAD-free and graft survival and maintains pulmonary function. Therefore, early P. aeruginosa detection and eradication should be pursued.
Copyright ©ERS 2020.

Entities:  

Mesh:

Year:  2020        PMID: 32471935     DOI: 10.1183/13993003.01720-2020

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  5 in total

Review 1.  Antibiotic Therapy for Difficult-to-Treat Infections in Lung Transplant Recipients: A Practical Approach.

Authors:  Lorena van den Bogaart; Oriol Manuel
Journal:  Antibiotics (Basel)       Date:  2022-05-02

Review 2.  Challenges in the use of highly effective modulator treatment for cystic fibrosis.

Authors:  Kathleen J Ramos; Joseph M Pilewski; Jennifer L Taylor-Cousar
Journal:  J Cyst Fibros       Date:  2021-01-30       Impact factor: 5.482

3.  Can we decloak how infections drive complications after lung transplantation?

Authors:  Hrishikesh S Kulkarni; Erika D Lease
Journal:  J Heart Lung Transplant       Date:  2021-05-29       Impact factor: 13.569

4.  Exacerbation of chronic renal failure because of inhaled tobramycin in a lung transplant patient.

Authors:  Víctor M Mora Cuesta; Noelia Borja Vargas; David Iturbe Fernández; Sandra Tello Mena; José M Cifrián Martínez
Journal:  Respir Med Case Rep       Date:  2022-01-22

5.  Outcome and prognostic factors after lung transplantation for bronchiectasis other than cystic fibrosis.

Authors:  Takashi Hirama; Fumiko Tomiyama; Hirotsugu Notsuda; Tatsuaki Watanabe; Yui Watanabe; Hisashi Oishi; Yoshinori Okada
Journal:  BMC Pulm Med       Date:  2021-08-13       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.